StockData
Beam Therapeutics Inc. logo

Beam Therapeutics Inc. (BEAM) stock

BEAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3014% below fair value
$20.65−0.29 (-1.38%)

Close on Nov 17, 2026Market cap $2.13BP/E –Yield –

Beam Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Beam Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $156.04M, up 158.9% year over year. For fiscal 2025 it was $139.74M, up 120.0% from the year before. The highest annual figure on record is $377.71M in fiscal 2023.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$139.74M+120.0%
FY2024Dec 31, 2024$63.52M-83.2%
FY2023Dec 31, 2023$377.71M+520.0%
FY2022Dec 31, 2022$60.92M+17.5%
FY2021Dec 31, 2021$51.84M+215916.7%
FY2020Dec 31, 2020$24.00K+33.3%
FY2019Dec 31, 2019$18.00K–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$490.00K-94.2%
Q1 FY2026Mar 31, 2026$31.74M+324.9%
Q4 FY2025Dec 31, 2025$114.11M+279.5%
Q3 FY2025Sep 30, 2025$9.70M-32.0%
Q2 FY2025Jun 30, 2025$8.47M-28.1%
Q1 FY2025Mar 31, 2025$7.47M+0.8%
Q4 FY2024Dec 31, 2024$30.07M-90.5%
Q3 FY2024Sep 30, 2024$14.27M-17.0%
Q2 FY2024Jun 30, 2024$11.77M-41.5%
Q1 FY2024Mar 31, 2024$7.41M-69.4%
Q4 FY2023Dec 31, 2023$316.19M+1478.0%
Q3 FY2023Sep 30, 2023$17.19M+8.8%
Q2 FY2023Jun 30, 2023$20.12M+20.8%
Q1 FY2023Mar 31, 2023$24.21M+187.1%
Q4 FY2022Dec 31, 2022$20.04M-60.8%
Q3 FY2022Sep 30, 2022$15.80M+1970.6%
Q2 FY2022Jun 30, 2022$16.65M+277433.3%
Q1 FY2022Mar 31, 2022$8.43M+140433.3%
Q4 FY2021Dec 31, 2021$51.07M+851050.0%
Q3 FY2021Sep 30, 2021$763.00K+12616.7%
Q2 FY2021Jun 30, 2021$6.00K0.0%
Q1 FY2021Mar 31, 2021$6.00K0.0%
Q4 FY2020Dec 31, 2020$6.00K0.0%
Q3 FY2020Sep 30, 2020$6.00K0.0%
Q2 FY2020Jun 30, 2020$6.00K0.0%
Q1 FY2020Mar 31, 2020$6.00K–
Q4 FY2019Dec 31, 2019$6.00K–
Q3 FY2019Sep 30, 2019$6.00K–
Q2 FY2019Jun 30, 2019$6.00K–

More Beam Therapeutics figures

See a number that looks wrong?